Now out of business, Genetica had been a privately held biotechnology company focused on cellular genetics, in particular the use of a novel set of genetic tools both to enhance the pace of drug discovery and to genetically manipulate cultured cells and whole organisms. Fiarly active inthe SBIR arena, Genetica's unique approach was being used as a means to determine disease pathways in human cells, validate targets for small molecule drug discovery, and discover novel biopharmaceuticals and diagnostics.
